Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

被引：80

作者：

Yerly, S ^{[1
]}

Günthard, HF

Fagard, C

Joos, B

Perneger, TV

Hirschel, B

Perrin, L

机构：

[1] Univ Hosp Geneva, Virol Lab, Geneva, Switzerland

[2] Univ Hosp Geneva, AIDS Ctr, Geneva, Switzerland

[3] Univ Hosp Geneva, Dept Social & Prevent Med, Geneva, Switzerland

[4] Univ Zurich Hosp, Div Infect Dis, CH-8091 Zurich, Switzerland

来源：

AIDS | 2004年 / 18卷 / 14期

关键词：

D O I：

10.1097/00002030-200409240-00011

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In HIV-1-infected patients with long-term undetectable viraemia on highly active antiretroviral treatment (HAART), we found that pre-HAART plasma viraemia and the baseline proviral DNA level were significantly associated with the viraemia setpoint during scheduled treatment interruptions. In long-term treated patients, pre-HAART viraemia may not be available, and in these circumstances proviral DNA, measured at the time of scheduled treatment interruption, can help to identify patients likely to reach a low viraemia setpoint after treatment interruption.

引用

页码：1951 / 1953

页数：3

共 20 条

[1] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].

Carr, A ;

Samaras, K ;

Thorisdottir, A ;

Kaufmann, GR ;

Chisholm, DJ ;

Cooper, DA .

LANCET, 1999, 353 (9170) :2093-2099

[2] Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters [J].

Dybul, M ;

Chun, TW ;

Yoder, C ;

Hidalgo, B ;

Belson, M ;

Hertogs, K ;

Larder, B ;

Dewar, RL ;

Fox, CH ;

Hallahan, CW ;

Justement, JS ;

Migueles, SA ;

Metcalf, JA ;

Davey, RT ;

Daucher, M ;

Pandya, P ;

Baseler, M ;

Ward, DJ ;

Fauci, AS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) :15161-15166

[3] A prospective trial of structured treatment interruptions in human immunodeficiency virus infection [J].

Fagard, C ;

Oxenius, A ;

Günthard, H ;

Garcia, F ;

Le Braz, M ;

Mestre, G ;

Battegay, M ;

Furrer, H ;

Vernazza, P ;

Bernasconi, E ;

Telenti, A ;

Weber, R ;

Leduc, D ;

Yerly, S ;

Price, D ;

Dawson, SJ ;

Klimkait, T ;

Perneger, TV ;

McLean, A ;

Clotet, B ;

Gatell, JM ;

Perrin, L ;

Plana, M ;

Phillips, R ;

Hirschel, B .

ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (10) :1220-1226

[4] Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy [J].

Fischer, M ;

Joos, B ;

Wong, JK ;

Ott, P ;

Opravil, M ;

Hirschel, B ;

Weber, R ;

Günthard, HF .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (02) :273-285

[5] HIV RNA in plasma rebounds within days during structured treatment interruptions [J].

Fischer, M ;

Hafner, R ;

Schneider, C ;

Trkola, A ;

Joos, B ;

Joller, H ;

Hirschel, B ;

Weber, R ;

Günthard, HF .

AIDS, 2003, 17 (02) :195-199

[6] Time trends in primary HIV-1 drug resistance among recently infected persons [J].

Grant, RM ;

Hecht, FM ;

Warmerdam, M ;

Liu, L ;

Liegler, T ;

Petropoulos, CJ ;

Hellmann, NS ;

Chesney, M ;

Busch, MP ;

Kahn, JO .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :181-188

[7] Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy [J].

Havlir, DV ;

Marschner, IC ;

Hirsch, MS ;

Collier, AC ;

Tebas, P ;

Bassett, RL ;

Ioannidis, JPA ;

Holohan, MK ;

Leavitt, R ;

Boone, G ;

Richman, DD .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) :1261-1268

[8] Cell-associated HIV DNA measured early during infection has prognostic value independent of serum HIV RNA measured concomitantly [J].

Katzenstein, TL ;

Oliveri, RS ;

Benfield, T ;

Eugen-Olsen, J ;

Nielsen, C ;

Gerstoft, J .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2002, 34 (07) :529-533

[9] Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies [J].

Lafeuillade, A ;

Poggi, C ;

Hittinger, G ;

Counillon, E ;

Emilie, D .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (10) :1426-1432

[10] Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy [J].

McDermott, JL ;

Giri, AA ;

Martini, I ;

Bono, M ;

Giacomini, M ;

Campelli, A ;

Tagliaferro, L ;

Cara, A ;

Varnier, OE .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (07) :2361-2365

← 1 2 →